Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients

Completed

Conditions studied: Myelodysplastic Syndrome, Acute Myeloblastic Leukemia, Leukemia

In brief

Primary Objective: 1\. To assess the self-reported symptoms and the plasma cytokine levels of AML/MDS patients pretransplantation and posttransplantation with allogeneic blood and marrow in order to identify changes in symptoms (or symptom clusters) and changes in cytokines that may be related to the conditioning regimen and/or to the development of GVHD during the 100 days posttransplant. Based on the current literature, both animal and human research, in this study we hypothesize that increases in TNF alpha to be associated with poor appetite, sleep disturbance and fatigue, but not with increases in pain, depression and numbness.

Key facts

Study ID

NCT00504920

Run by

M.D. Anderson Cancer Center

People needed

30

Starts

2004-05-01

Expected to finish

2008-09-01

Last updated by the study team

2012-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients scheduled for allogeneic transplantation (bone marrow or peripheral blood stem cell) at MDACC.
• Adults > = 18 years old.
• Patients with a diagnosis of AML or MDS
• Patients who are English-speaking
• Patients who live in the United States
• Patients with adequate vision and hearing to use the interactive voice response (IVR) telephone system
• Patients who provide written informed consent/authorization

You may not qualify if…

• Patients with a current diagnosis of psychosis or dementia
• Patients who are unable to complete the assessment measures or refuse to participate

Where it is running

• U.T.M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.